Pfizer said its experimental anti-PD-1 drug bested the current standard of care in a type of bladder cancer where progress has been limited. Its therapy … ...
Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new ...
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it ...
Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...
Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, will step down, the agency confirmed ...
With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The ...
Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...
City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...
Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...
Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback